Importance of dose timing to achieving undetectable viral loads

AIDS and Behavior

Volumn 14, Issue 4, 2010, Pages 785-793

  Gill, Christopher J ^a,b   Sabin, Lora L ^a   Hamer, Davidson H ^a,b   Keyi, Xu ^c   Jianbo, Zhang ^d   Li, Tao ^a   Wu, Wan Ju ^a   Wilson, Ira B ^e   DeSilva, Mary Bachman ^a  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Dali Second People's Hospital   (China)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

Adherence; Antiretroviral therapy; China; Dose timing; HIV AIDS; Non nucleoside reverse transcriptase inhibitor

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; ASIAN; CD4 LYMPHOCYTE COUNT; CHINA; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SOCIOECONOMICS; STATISTICS; TIME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CD4 LYMPHOCYTE COUNT; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SOCIOECONOMIC FACTORS; TIME FACTORS; VIRAL LOAD;

EID: 77956872872     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-009-9555-9     Document Type: Article

References (25)

1. Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(8), 1417-1423. doi:10.1086/ 323201. (Pubitemid 32955198)
2. Bangsberg, D. R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43(7), 939-941. doi:10.1086/ 507526. (Pubitemid 44435526)
3. Bangsberg, D. R., Acosta, E. P., Gupta, R., Guzman, D., Riley, E. D., Harrigan, P. R., et al. (2006). Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (London, England), 20(2), 223-231. doi:10.1097/01.aids.0000199825. 34241.49.
4. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., et al. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England), 15(9), 1181-1183. doi:10.1097/ 00002030-200106150-00015.
5. de Olalla, P. G., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomez, J. L., & Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes, 30(1), 105-110. doi:10.1097/00126334-200205010- 00014. (Pubitemid 34506694)
6. Gardner, E. M., Sharma, S., Peng, G., Hullsiek, K. H., Burman, W. J., Macarthur, R. D., et al. (2008). Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS (London, England), 22(1), 75-82. doi:10.1097/QAD.0b013e3282f366ff. (Pubitemid 350294880)
7. George, C. F., Peveler, R. C., Heiliger, S., & Thompson, C. (2000). Compliance with tricyclic antidepressants: The value of four different methods of assessment. British Journal of Clinical Pharmacology, 50(2), 166-171. doi:10.1046/j.1365-2125.2000. 00244.x.
8. Gill, C. J., Hamer, D. H., Bachman-DeSilva, M., Heggenhougen, H. K., Keyi, X., Yuan, Y., et al. (2006). Divergent views regarding adherence to antiretroviral therapy between clinicians and their patients in Dali, Yunnan Province, China (Abstract: WEPE0103). Paper presented at the XVI International AIDS Conference, Toronto, Canada.
9. Gross, R., Bilker, W. B., Friedman, H. M., & Strom, B. L. (2001). Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS (London, England), 15(16), 2109-2117. doi:10.1097/00002030-200111090- 00006. (Pubitemid 33101818)
10. Harrell, F. E., Jr, Lee, K. L., & Mark, D. B. (1996). Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine, 15(4), 361-387. doi:10.1002/(SICI)1097-0258(19960229)15:4\361:AID-SIM168[3.0.CO;2-4.
11. Hosmer, D. W., & Lemeshow, S. (2000). Applied logistic regression. New York: Wiley.
12. Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968-977.
13. Liu, H., Miller, L. G., Golin, C. E., Hays, R. D., Wu, T., Wenger, N. S., et al. (2007). Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes. Statistics in Medicine, 26(5), 991-1007. doi:10.1002/ sim.2592.
14. Lu, M., Safren, S. A., Skolnik, P. R., Rogers, W. H., Coady, W., Hardy, H., et al. (2008). Optimal recall period and response task for self-reported HIV medication adherence. AIDS and Behavior, 12(1), 86-94. doi:10.1007/s10461-007- 9261-4. (Pubitemid 351143454)
15. Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115-1121. doi:10.1086/339074. (Pubitemid 34289685)
16. McNabb, J., Ross, J. W., Abriola, K., Turley, C., Nightingale, C. H., & Nicolau, D. P. (2001). Adherence to highly active antiretro-viral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clinical Infectious Diseases, 33(5), 700-705. doi:10.1086/322590. (Pubitemid 32762944)
17. Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., & Maartens, G. (2007). Adherence to nonnu-cleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Annals of Internal Medicine, 146(8), 564-573.
18. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21-30.
19. Rudd, P., Byyny, R. L., Zachary, V., LoVerde, M. E., Titus, C., Mitchell, W. D., et al. (1989). The natural history of medication compliance in a drug trial: Limitations of pill counts. Clinical Pharmacology and Therapeutics, 46(2), 169-176.
20. Sabin, L., Bachman-DeSilva, M., Hamer, D. H., Keyi, X., Yuan, Y., Fan, W., et al. (2008). Barriers to adherence among patients on antiretroviral medications in southern China: A qualitative study. AIDS Care.
21. Sanford, J. P. (2005). The Sanford guide to HIV/AIDS therapy 2005 (14th ed.). Sperryville, VA: Antimicrobial Therapy Inc.
22. San Lio, M. M., Carbini, R., Germano, P., Guidotti, G., Mancinelli, S., Magid, N. A., et al. (2008). Evaluating adherence to highly active antiretroviral therapy with use of pill counts and viral load measurement in the drug resources enhancement against AIDS and malnutrition program in Mozambique. Clinical Infectious Diseases, 46(10), 1609-1616. doi:10.1086/587659. (Pubitemid 351706745)
23. Simoni, J. M., Kurth, A. E., Pearson, C. R., Pantalone, D. W., Merrill, J. O., & Frick, P. A. (2006). Self-report measures of antiretro-viral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS and Behavior, 10(3), 227-245. doi:10.1007/s10461-006-9078-6.
24. Walter, S. D. (2002). Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Statistics in Medicine, 21(9), 1237-1256. doi:10.1002/sim.1099. (Pubitemid 34467232)
25. Wilson, I. B., Tchetgen, E., & Spiegelman, D. (2001). Patterns of adherence with antiretroviral medications: An examination of between-medication differences. Journal of Acquired Immune Deficiency Syndromes, 28(3), 259-263.